Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Highly Effective Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Helps Overcome Social Determinants of Health in Medically Underserved Populations

Bradley Rockwell, Nitya Dhanaraj, Mark Forsberg, Swati Goel, David Levitz, Ridhi Gupta, Lauren Shapiro, Noah Kornblum, Eric J. Feldman

Blood (2024) 144 (Supplement 1): 3152.

https://doi.org/10.1182/blood-2024-210480

Published: 2024

Journal Articles

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova, Meixian Huang, Swati Goel, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose, Jo Ishizawa, Guillermo Montalban-Bravo, Mi-Ae Lyu, Tara Sadeghi, Simrit Parmar, Christopher R. Flowers, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 999.

https://doi.org/10.1182/blood-2024-211587

Published: 2024

Journal Articles

The Relationship between Sodium-Glucose Co-Transporter 2 Inhibitors and Erythrocytosis: A Retrospective Review from a Large Urban Center

Nitya Dhanaraj, Swati Goel

Blood (2024) 144 (Supplement 1): 2466.

https://doi.org/10.1182/blood-2024-204250

Published: 2024

Journal Articles

Differential Requirements for the RON Ligand Binding and Kinase Domains in Myeloproliferative Neoplasms

Alexandra Schurer, Lindsay Gurska, Yuxuan Wang, Allison Montoya, Swati Goel, Kira Gritsman

Blood (2024) 144 (Supplement 1): 1751.

https://doi.org/10.1182/blood-2024-210545

Published: 2024

Journal Articles

Assessing Epidemiological Differences in Myelofibrosis: A Comparative Study of a Single-Center Cohort and the SEER National Database

John Yan, John X Wei, Amit Verma, Nishi Shah, Swati Goel

Blood (2023) 142 (Supplement 1): 7426.

https://doi.org/10.1182/blood-2023-184932

Published: 2023

Journal Articles

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2023-185379

Published: 2023

Journal Articles

High PD-L1 Expression May be Associated with Worse Overall Prognosis in Acute Myeloid Leukemia

Josette M Kamel, Mendel Goldfinger, Jiani Chai, Jui Choudhuri, Marina Y. Konopleva, Eric J Feldman, Ioannis Mantzaris, Dennis L Cooper, Aditi Shastri, Nishi Shah, Noah Kornblum, Kira Gritsman, Alejandro Sica, Yanhua Wang, Xuejun Tian, Amit Verma, Swati Goel

Blood (2023) 142 (Supplement 1): 6050.

https://doi.org/10.1182/blood-2023-188243

Published: 2023

Journal Articles

Evaluation of CNS Involvement in Secondary AML: Incidence and Impact on Outcome

Blood (2022) 140 (Supplement 1): 11653–11655.

https://doi.org/10.1182/blood-2022-158112

Published: 2022

Journal Articles

Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia

Jiani Chai, Jui Choudhuri, Qing Wang, Yanan Fang, Yang Shi, Wa Shen, Swati Goel, Ioannis Mantzaris, Aditi Shastri, R. Alejandro Sica, Nishi Shah, Kira Gritsman, Marina Konopleva, Noah Kornblum, Amit Verma, Mendel Goldfinger, Yanhua Wang, Xuejun Tian

Blood (2022) 140 (Supplement 1): 6256–6257.

https://doi.org/10.1182/blood-2022-162857

Published: 2022

Journal Articles

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice Wang, Aaron T. Gerds, Gabriela S. Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen T Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2022) 140 (Supplement 1): 579–582.

https://doi.org/10.1182/blood-2022-160384

Published: 2022

Journal Articles

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Blood (2021) 138 (Supplement 1): 3647.

https://doi.org/10.1182/blood-2021-148668

Published: 2021

Journal Articles

RON Kinase Is a Novel Therapeutic Target for Philadelphia-Negative Myeloproliferative Neoplasms

Lindsay Meg Gurska, Rachel Okabe, Meng Maxine Tong, Daniel Choi, Kristina Ames, Shira Glushakow-Smith, Allison Montoya, Ellen Tein, Haiying Cheng, Swati Goel, Balazs Halmos, Kira Gritsman

Blood (2021) 138 (Supplement 1): 1462.

https://doi.org/10.1182/blood-2021-148192

Published: 2021

Journal Articles

Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-139229

Published: 2020

Journal Articles

Direct Oral Anticoagulants for Prevention of Recurrent Thrombosis in Myeloproliferative Neoplasms

Kateryna Fedorov, MD, Swati Goel, MD, Margarita Kushnir, MD, Henny H. Billett, MD

Blood (2019) 134 (Supplement_1): 4193.

https://doi.org/10.1182/blood-2019-127600

Published: 2019

Journal Articles

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Stephen T Oh, MD PhD, Moshe Talpaz, MD, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD FACP, Carole Brennan Miller, MD, Candido E. Rivera, MD, Angela Fleischman, MD PhD, Swati Goel, Mark L Heaney, MD PhD, Casey O'Connell, MD, Murat Arcasoy, MD, Yafeng Zhang, PhD MD, Jun Kawashima, MD, Tomas Ganz, MD PhD, Carrie Baker Brachmann

Blood (2018) 132 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2018-99-111349

Published: 2018

Journal Articles

North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies

Blood (2018) 132 (14): 1507–1518.

https://doi.org/10.1182/blood-2018-01-824607

Published: 2018

Includes: Supplemental data

Journal Articles

Obesity Is Associated with Younger Age at Presentation and More Severe Cytopenias in Myelodysplastic Syndromes

Santiago Thibaud, MD, Diego Adrianzen Herrera, MD, Rosebella Snyder, Justin D. Kaner, MD, Ioannis Mantzaris, MD, Swati Goel, MD, Amit Verma, MD, Aditi Shastri, MD

Blood (2017) 130 (Supplement 1): 5312.

https://doi.org/10.1182/blood.V130.Suppl_1.5312.5312

Published: 2017

Journal Articles

North American Adult T Cell Leukemia Lymphoma (ATLL) Is Characterized By Distinct, Therapeutically Targetable Mutations in Epigenetic Modifiers

Blood (2017) 130 (Supplement 1): 1455.

https://doi.org/10.1182/blood.V130.Suppl_1.1455.1455

Published: 2017

Journal Articles

HIV Is Associated with a High Rate of Unexplained Multilineage Cytopenias and Portends a Poor Prognosis in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Justin Kaner, MD, Santiago Thibaud, MD, Ashwin Sridharan, MD, Amer Assal, MD, Rahul Polineni, MD, Barry Zingman, MD, Anjali Sharma, MD, Harold Kunal Elias, MD, Louis Weiss, MD MPH, Murali Janakiram, MD, Ira Braunschweig, MD, Swati Goel, MD, Ulrich Steidl, MDPhD, Kith Pradhan, PhD, Aditi Shastri, MD, Britta Will, PhD, Ioannis Mantzaris, MD, Mark Chaitowitz, MD, Amit Verma, MD

Blood (2016) 128 (22): 4345.

https://doi.org/10.1182/blood.V128.22.4345.4345

Published: 2016

Journal Articles

Hematology Referrals for Leukopenia in the Bronx Rarely Result in Clinically Significant Diagnoses: First Steps Towards and Evidence-Based Referral Guideline

Mark Chaitowitz, MD, Van Metre Laura, MD, Swati Goel, MD

Blood (2016) 128 (22): 4743.

https://doi.org/10.1182/blood.V128.22.4743.4743

Published: 2016

NARROW

Highly Effective Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Helps Overcome Social Determinants of Health in Medically Underserved Populations

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

The Relationship between Sodium-Glucose Co-Transporter 2 Inhibitors and Erythrocytosis: A Retrospective Review from a Large Urban Center

Differential Requirements for the RON Ligand Binding and Kinase Domains in Myeloproliferative Neoplasms

Assessing Epidemiological Differences in Myelofibrosis: A Comparative Study of a Single-Center Cohort and the SEER National Database

Effective and Safe Molecular-Pharmacodynamic Once Weekly Dosing of Decitabine and Venetoclax Is a Highly Effective and Well-Tolerated Induction Therapy for AML: Interim Results of a Phase 2 Trial

High PD-L1 Expression May be Associated with Worse Overall Prognosis in Acute Myeloid Leukemia

Evaluation of CNS Involvement in Secondary AML: Incidence and Impact on Outcome

Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

RON Kinase Is a Novel Therapeutic Target for Philadelphia-Negative Myeloproliferative Neoplasms

Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients

Direct Oral Anticoagulants for Prevention of Recurrent Thrombosis in Myeloproliferative Neoplasms

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies

Obesity Is Associated with Younger Age at Presentation and More Severe Cytopenias in Myelodysplastic Syndromes

North American Adult T Cell Leukemia Lymphoma (ATLL) Is Characterized By Distinct, Therapeutically Targetable Mutations in Epigenetic Modifiers

HIV Is Associated with a High Rate of Unexplained Multilineage Cytopenias and Portends a Poor Prognosis in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Hematology Referrals for Leukopenia in the Bronx Rarely Result in Clinically Significant Diagnoses: First Steps Towards and Evidence-Based Referral Guideline

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only